Empirical use of temocillin in hospitalized patients: results from a retrospective audit. Issue 2 (19th April 2023)

• Record Type: Journal Article
• Authors: Kandil, Hala; Gray, Robert M; El-Hamad, Rakan; Vidwans, Madhuri; Vaghela, Tejal; Naji, Omar; Van De Velde, Sebastien
• Is Part Of: JAC-antimicrobial resistance. Volume 5:Issue 2(2023)
• Publication Date: 2023-04-19
• Subjects: Anti-infective agents -- Periodicals; Chemotherapy -- Periodicals; Drug resistance in microorganisms -- Periodicals; 616.9041
• DOI: 10.1093/jacamr/dlad030
• Languages: English
• ISSNs: 2632-1823

Abstract

Abstract: Background: Following a global shortage of piperacillin/tazobactam in 2017, a formulary decision was taken at a large District General Hospital in the East of England to partly replace piperacillin/tazobactam with either temocillin as monotherapy or as part of a combination regimen. A retrospective audit was then conducted to assess the clinical effectiveness of temocillin therapy. Methods: Data from patients admitted to Watford General Hospital between May and August 2017 and treated with temocillin were reviewed retrospectively. Clinical characteristics of patients, data related to the episode of infection, clinical success, tolerance and mortality were analysed. Results: Temocillin was used in 126 patients with median age of 73 years. Infection episodes mostly originated from the abdomen ( n = 46), the lung ( n = 40) and the urinary tract ( n = 21). Seventy-seven patients received temocillin as first-line therapy and 106 received it empirically, with temocillin prescribed in combination with another antibiotic in 82% of the empirically treated cases. Clinical success was observed in 88.9% of cases with no difference between patients treated empirically and others (89.6% versus 85%) or in efficacy among abdominal (91%), pulmonary (87.5%) and urinary (81%) infections. One case of Clostridioides difficile infection was reported in a patient treated with four different antibiotics. During the shortage period, the hospital's standardized mortality ratio was significantly lower when compared with the same period of the preceding year (85 versus 96). Conclusions: Using temocillin as part of an empirical strategy is feasible and safe as long as appropriate antibiotic combination is recommended based upon the indication and the likely bacterial pathogen.